Strides Pharma to monetise stake in Pivot Path; company valued at ₹230 crore post
Published on: June 27, 2026, 5:37 p.m. | Source: CNBC TV18
Strides Pharma Science Limited will monetise its stake in subsidiary Pivot Path Private Limited in a transaction led by Ascent Capital, alongside co-investor Vintage Classic, valuing the entity at near ₹230 crore post-money. The company will realise near ₹100 crore while retaining near 20% ownership and also receive a primary capital infusion of ₹50 crore into the business.
